MAPT and tauopathy: Recently, we showed that β-arrestin2 oligomers mediate tauopathy by impairing pathogenic tau clearance (Woo et al, 2020), and β-arrestin2 oligomerization mutants show dominant-negative “anti-oligomer” effects in vitro and in vivo.